Opis działalności
Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. Headquartered in Leverkusen, Germany, Biofrontera is a publicly listed on the Frankfurt Stock Exchange (Prime Standard) and London Stock Exchange (AIM) – B8F / ISIN: DE 0006046113. In February 2012 Biofrontera launched its prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through local partners. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this purpose Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012. As cosmeceutical products Biofrontera markets Belixos® for the regenerative care of reddened and inflamed skin. Biofrontera developed a line of cosmeceutical products for damaged skin under the Belixos brand. The product portfolio includes the Belixos® cream, Belixos LIQUID®, Belixos® GEL and DayCare cream Belixos® PROTECT.
Zarząd & Rada nadzorcza
CEO |
- |
Zarząd |
Ludwig Lutter |
Rada nadzorcza |
Wilhelm K. T. Zours, Dr. Jörgen Tielmann, Dr. Heikki Lanckriet, Dr. Helge Lubenow, Karlheinz Schmelig, Prof. Dr. Franca Ruhwedel |
Dane firmy
Nazwa: |
Biofrontera AG |
Adres: |
Hemmelrather Weg 201,D-51377 Leverkusen |
Telefon: |
+49-214-87632-0 |
Fax: |
+49-214-87632-90 |
E-mail: |
info@biofrontera.com
|
Internet: |
www.biofrontera.com |
Przemysł: |
Służba zdrowia |
Sektor: |
Przemysł Farmaceutyczny |
Podsektor: |
Przemysł Farmaceutyczny |
Koniec roku finansowego: |
31.12 |
Free float: |
46,41% |
Data IPO: |
- |